Welcome to Mitovation
Mitovation’s Non-Invasive Mitochondrial Modulation Therapy is a Platform Technology to Address Multiple MarketsLet's talk
Mitovation’s infrared light technology is non-invasive and has a robust safety profile.
Mitovation has filed and been issued multiple patents for its technology in the United States and Internationally.
Class II Regulatory pathway
Mitovation’s device qualifies as a Class II Medical device 510k de novo clearance through the Food and Drug Administration.
Experienced leadership team
Mitovation’s leadership team and advisory board have depth and breadth of experience in translating medical devices from bench to bedside.
Exclusive License Option
Mitovation has an exclusive license to its infrared technology through Wayne State University’s Office of Technology Commercialization and the University of Michigan.
NIH and DoD funded
To date, Mitovation and its founders have been awarded ~$21 Million in grant and award funds from the NIH, DoD, and others to research, develop, and commercialize its groundbreaking technology.